Insulin Glargine

US FDA
Manufacturing

Viatris kicked off its third insulin biosim recall this year

After seven months and two prior recalls, Viatris continues to be vexed by labeling issues on its biosimilar to Sanofi’s diabetes blockbuster Lantus.
Fraiser Kansteiner Jul 6, 2022 9:08am
FDA recall creative image

Viatris is pulling another insulin batch following a label snafu

Apr 13, 2022 9:25am
Semglee Viatris

Viatris rolls out branded and unbranded forms of insulin biosim

Nov 16, 2021 10:41am
Sanofi CEO speech

Sanofi hails China performance, downplays biosimilar threat in Japan

May 2, 2016 4:31am